Merck & Co., Inc. (Merck (MRK)) just took a big L in court. A federal court fully denied the company's motion for summary judgment and granted the federal government's cross-motion, effectively upholding the Inflation Reduction Act's Drug Price Negotiation Program. This is a major win for the Biden administration's efforts to lower prescription drug costs for Medicare beneficiaries.
Merck had challenged the program on constitutional grounds, arguing that it amounts to uncompensated property takings under the Fifth Amendment, compelled speech under the First Amendment, and unconstitutional conditions on program participation. The court wasn't having any of it.
Medicare Part D Pricing Exceptions
Let's rewind a bit. Congress created Medicare Part D back in 2003 as a voluntary prescription drug benefit program, administered by the Centers for Medicare and Medicaid Services through public-private partnerships. Initially, the law explicitly barred federal officials from setting price structures or interfering in private price negotiations. That was the deal.
But then the Inflation Reduction Act came along and changed the game. It created a statutory exception that directs federal administrators to negotiate maximum fair prices for designated high-expenditure drugs that lack generic competitors and have maintained regulatory approval for at least seven years. In other words, the government now has a seat at the negotiating table for certain expensive drugs.
Negotiation Rules And Price Caps
Under the program's guidelines, federal administrators are instructed to seek the lowest maximum fair price for each chosen drug, with negotiations capped at 75% of the private market value. So there's a ceiling on how much the government can push prices down, but it's still a significant intervention.
Drugmakers that participate must execute official agreements and addendums, guaranteeing Medicare beneficiaries access to the agreed prices until generic alternatives hit the market. That's a key part of the deal: in exchange for participating, drugmakers get certainty about the pricing framework, but they have to commit to providing the drug at the negotiated price for a set period.
Escalating Excise Tax Penalties
Here's where things get really interesting. If a pharmaceutical company decides to sit out the program or fails to reach a pricing agreement, they face severe daily excise taxes on all their product sales—and that includes non-Medicare transactions. This isn't just a slap on the wrist; it's a financial hammer.
The penalties start at 185.71% of the drug's sales price on day one of noncompliance and escalate up to a whopping 1,900% after 270 days. That's not a typo. The tax is designed to be so punitive that it forces companies to either comply or exit the market entirely.
Noncompliant manufacturers can avoid these escalating penalties only by divesting the drug or completely withdrawing all their products from Medicare Part D and Medicaid rebate programs. So the choice is stark: play ball with the government's pricing, or lose access to a huge chunk of the U.S. drug market.
MRK Stock Price Activity: Merck shares were down 0.20% at $150.36 during premarket trading on Tuesday, according to market data.
